IDH2 and glioblastoma: The classification also includes TERT promoter mutation, EGFR gene amplification, and combined gain of entire chromosome 7 and loss of entire chromosome 10 (+7/−10) as qualifying for the diagnosis of GBM, IDH-wildtype.